dwashington3 on PRODPC61 with NOTICES3

Federal Register / Vol. 73, No. 139 / Friday, July 18, 2008 / Notices 41357 

can also be submitted by e-mail to 

OCAS@CDC.GOV. 

Dated: July 2, 2008. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. E8–16467 Filed 7–17–08; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institute for Occupational 

Safety and Health; Final Effect of 

Designation of a Class of Employees 

for Addition to the Special Exposure 

Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) gives notice 

concerning the final effect of the HHS 

decision to designate a class of 

employees at the Nuclear Materials and 

Equipment Corporation (NUMEC) 

facility in Parks Township, 

Pennsylvania, as an addition to the 

Special Exposure Cohort (SEC) under 

the Energy Employees Occupational 

Illness Compensation Program Act of 

2000. On May 30, 2008, as provided for 

under 42 U.S.C. 7384q(b), the Secretary 

of HHS designated the following class of 

employees as an addition to the SEC: 

All Atomic Weapons Employer (AWE) 

employees who worked at the Nuclear 

Materials and Equipment Corporation 

(NUMEC) facility in Parks Township, 

Pennsylvania, from June 1, 1960, through 

December 31, 1980, for a number of work 

days aggregating at least 250 work days 

occurring either solely under this 

employment or in combination with work 

days within the parameters established for 

one or more other classes of employees in the 

Special Exposure Cohort. 

This designation became effective on 

June 29, 2008, as provided for under 42 

U.S.C. 7384l(14)(C). Hence, beginning 

on June 29, 2008, members of this class 

of employees, defined as reported in 

this notice, became members of the 

Special Exposure Cohort. 

FOR FURTHER INFORMATION CONTACT: 

Larry Elliott, Director, Office of 

Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, telephone 1– 

800–CDC–INFO (1–800–232–4636) or 

directly at 1–513–533–6800 (this is not 

a toll-free number). Information requests 

can also be submitted by e-mail to 

OCAS@CDC.GOV. 

Dated: July 2, 2008. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. E8–16468 Filed 7–17–08; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Scientific Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

and the Assistant Secretary for Health 

have taken final action in the following 

case: 

J. Keith Hampton, St. Luke’s Hospital: 

Based on the report of an investigation 

conducted by St. Luke’s Hospital (SLH) 

in Chesterfield, MO, and additional 

analysis conducted by the Office of 

Research Integrity (ORI) during its 

oversight review, the U.S. Public Health 

Service (PHS) found that J. Keith 

Hampton, MSN, APRN, former Clinical 

Research Associate, SLH, engaged in 

scientific misconduct in research 

supported by National Cancer Institute 

(NCI), National Institutes of Health 

(NIH), awards U10 CA69651, U10 

CA12027, and U10 CA33601. 

PHS found that Mr. Hampton engaged 

in scientific misconduct by falsifying 

and fabricating data that were reported 

to the National Surgical Adjuvant Breast 

& Bowel Project (NSABP) and Cancer 

and Leukemia Group B (CALGB) 

cooperative research groups. 

Specifically, PHS found that: 

1. For protocol CALGB 90206, 

Respondent: 

(a) Falsified a patient’s CT scan 

reports and registration forms and 

reported the falsified CT scan reports 

and registration worksheet to CALGB, 

(b) Falsified a patient’s performance 

status records (giving 80% performance 

status) and registration forms and 

reported the falsified performance status 

report and registration form to CALGB. 

2. For protocol NSABP B–35, 

Respondent: 

(a) Falsified eligibility data related to 

hematology and chemistry assays and to 

the performance of a pelvic exam on one 

patient’s registration form and reported 

the falsified registration forms to the 

National Cancer Institute Cancer Trial 

Support Unit (CTSU), 

(b) Falsified pelvic exam eligibility on 

a second patient’s registration form and 

reported the falsified registration form 

to the CTSU, 

(c) Falsified hematology and 

chemistry assay eligibility on a third 

patient’s registration form and reported 

the falsified registration form to the 

CTSU. 

3. For protocol NSABP B–36, 

Respondent falsified a patient’s 

multigated acquisition test (MUGA—a 

test of heart function) records, cardiac 

function, and registration forms, 

certified the patient’s eligibility, and 

reported the falsified MUGA test, 

cardiac function, and registration forms 

to the CTSU. 

4. For protocol NSABP B–38, 

Respondent falsified hematology, 

chemistry, and MUGA eligibility for a 

patient on the registration form and 

reported the falsified registration form 

to the CTSU. 

5. For protocol NSABP C–08, 

Respondent: 

(a) Falsified urine protein/creatinine 

ratio eligibility for one patient on the 

registration form and reported the 

falsified registration form to the CTSU, 

(b) Falsified urine protein/creatinine 

ratio eligibility for a second patient on 

the registration form and reported the 

falsified registration form to the CTSU, 

(c) Falsified claims of the urine 

protein/creatinine ratio and PT(INR) 

eligibility for a third patient on the 

registration form and reported the 

falsified registration form to the CTSU. 

6. For protocol NSABP R–04, 

Respondent falsified a patient’s 

colonoscopy report and eligibility at 

registration and reported the falsified 

colonoscopy report and registration 

form to the CTSU. 

Mr. Hampton has entered into a 

Voluntary Exclusion Agreement 

(Agreement) in which he has voluntarily 

agreed for a period of three (3) years, 

beginning on June 17, 2008: 

(1) To exclude himself from any 

contracting or subcontracting with any 

agency of the United States Government 

and from eligibility or involvement in 

nonprocurement programs of the United 

States Government referred to as 

‘‘covered transactions’’ pursuant to 

HHS’ Implementation (2 CFR part 376 et 

seq.) of OMB Guidelines to Agencies on 

Governmentwide Debarment and 

Suspension (2 CFR part 180); and 

(2) To exclude himself from serving in 

any advisory capacity to PHS, including 

but not limited to service on any PHS 

advisory committee, board, and/or peer 

review committee, or as a consultant or 

contractor to PHS. 

FOR FURTHER INFORMATION CONTACT: 

Director, Division of Investigative 

Oversight, Office of Research Integrity,